Background image with text - Transforming live with less-invasive technologies engineered to diagnose and treat a wide range of medical conditions.
We’re dedicated to collaborating with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, increase efficiencies and—most importantly—help more people in more places around the world live longer, healthier lives.
Chart of 2018 Operational Sales
† Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments. The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment, which includes Cardiac Rhythm Management (CRM), Electrophysiology and Neuromodulation. In addition, we reclassified the Middle East and Africa (MEA) regions from the former AMEA region with Europe to create the new EMEA region. The new Asia-Pacific (APAC) region was also previously part of the former AMEA region. Prior year balances and year over year growth rates (denoted with “†”) have been revised accordingly. 1 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 55-57 of the 2018 Performance Report here:

Explore Our Businesses

Click to link to Endoscopy page,icon showing 1,500 technologies affecting 27 patients per minute
Click to link to Interventional Cardiology page - icon with 60 cardiovascular disease solutions
Link to Neuromodulation page.
Link to Peripheral Interventions page
Link to Rhythm Management page
Link to Urology and Pelvic Health page